Loading…
Reported covered position: Legislative Correspondent, Rep. Ackerman
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK INC. · Firm: DLA PIPER LLP (US)
Issues related to the prevention and treatment of diabetes, including diabetes screening; Implementation of Public Law No. 111-148, the Patient Protection and Affordable Care Act; S. Res. 242 and S. Res. 489, supporting the goals and ideals of "Growth Awareness Week"; H.R. 1074 and S. 539, National Diabetes Clinical Care Commission Act.
Preserving Access to Orphan Drugs Act of 2013
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: DLA PIPER LLP (US)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MILLENNIUM LABORATORIES via DLA PIPER LLP (US)
2014 · fourth_quarter · 4T
Medicare reimbursement and coverage issues related to diagnostic testing; Prescription drug abuse.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via DLA PIPER LLP (US)
2014 · fourth_quarter · 4T
Source: Senate LDA
Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; Patient access to therapies; H.R. 2315/S. 1128, Preserving Access to Orphan Drugs Act; H.R. 460, Patients Access to Treatments Act; H.R. 3116, Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act.
MODDERN Cures Act of 2013
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: DLA PIPER LLP (US)
Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; Patient access to therapies; H.R. 2315/S. 1128, Preserving Access to Orphan Drugs Act; H.R. 460, Patients Access to Treatments Act; H.R. 3116, Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act.
Patients' Access to Treatments Act of 2013
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: DLA PIPER LLP (US)
Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; Patient access to therapies; H.R. 2315/S. 1128, Preserving Access to Orphan Drugs Act; H.R. 460, Patients Access to Treatments Act; H.R. 3116, Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act.
Medicare Diabetes Prevention Act of 2013
Client: NOVO NORDISK INC. · Firm: DLA PIPER LLP (US)
Issues related to Medicare Part D and Medicaid rebates; H.R.962/S. 452, Medicare Diabetes Prevention Act of 2013.
Preserving Access to Orphan Drugs Act of 2013
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: DLA PIPER LLP (US)
Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; Patient access to therapies; H.R. 2315/S. 1128, Preserving Access to Orphan Drugs Act; H.R. 460, Patients Access to Treatments Act; H.R. 3116, Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act.
Issues related to Medicare Part D and Medicaid rebates; H.R.962/S. 452, Medicare Diabetes Prevention Act of 2013.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK INC. · Firm: DLA PIPER LLP (US)
Issues related to the prevention and treatment of diabetes, including diabetes screening; Implementation of Public Law No. 111-148, the Patient Protection and Affordable Care Act; S. Res. 242 and S. Res. 489, supporting the goals and ideals of "Growth Awareness Week"; H.R. 1074 and S. 539, National Diabetes Clinical Care Commission Act.
A resolution supporting the goals and ideals of "Growth Awareness Week".
Client: NOVO NORDISK INC. · Firm: DLA PIPER LLP (US)
Issues related to the prevention and treatment of diabetes, including diabetes screening; Implementation of Public Law No. 111-148, the Patient Protection and Affordable Care Act; S. Res. 242 and S. Res. 489, supporting the goals and ideals of "Growth Awareness Week"; H.R. 1074 and S. 539, National Diabetes Clinical Care Commission Act.
A resolution supporting the goals and ideals of "Growth Awareness Week".
Client: NOVO NORDISK INC. · Firm: DLA PIPER LLP (US)
Issues related to the prevention and treatment of diabetes, including diabetes screening; Implementation of Public Law No. 111-148, the Patient Protection and Affordable Care Act; S. Res. 242 and S. Res. 489, supporting the goals and ideals of "Growth Awareness Week"; H.R. 1074 and S. 539, National Diabetes Clinical Care Commission Act.
Issues related to Orphan drug designation; 21st Century Cures Initiative; Issues related to drug discovery and development; International Plasma Protein Awareness Week.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUMETRIX via DLA PIPER LLP (US)
2014 · third_quarter · Q3
Consumer access to health data and interoperability. H.R. 3230, Veterans Access Choice and Accountability Act of 2013, provisions related to health IT.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via DLA PIPER LLP (US)
2014 · third_quarter · Q3
Issues related to Orphan drug designation; 21st Century Cures Initiative; Issues related to drug discovery and development; International Plasma Protein Awareness Week.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via DLA PIPER LLP (US)
2014 · third_quarter · Q3
Issues related to the prevention and treatment of diabetes, including diabetes screening; Implementation of Public Law No. 111-148, the Patient Protection and Affordable Care Act; S. Res. 242 and S. Res. 489, supporting the goals and ideals of "Growth Awareness Week"; H.R. 1074 and S. 539, National Diabetes Clinical Care Commission Act.
Issues related to Medicare Part D and Medicaid rebates; H.R.962/S. 452, Medicare Diabetes Prevention Act of 2013.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM LABORATORIES via DLA PIPER LLP (US)
2014 · third_quarter · Q3
Medicare reimbursement and coverage issues related to diagnostic testing; Prescription drug abuse.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM LABORATORIES via DLA PIPER LLP (US)
2014 · second_quarter · Q2
Medicare reimbursement and prescription drug abuse.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via DLA PIPER LLP (US)
2014 · second_quarter · Q2
Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; Patient access to therapies; H.R. 2315/S. 1128, Preserving Access to Orphan Drugs Act; H.R. 460, Patients Access to Treatments Act; H.R. 3116, Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act.
Medicare reimbursement relating to plasma protein therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via DLA PIPER LLP (US)
2014 · second_quarter · RR
Medicare reimbrusement relating to plasma protein therapies; Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; patient access to therapies.
Medicare reimbrusement relating to plasma protein therapies; Orphan exemption to the annual pharmaceutical fee; Orphan drug tax credit; patient access to therapies.